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Microphysiological systems (MPSs) are in vitro models that capture facets of in vivo organ function 
through use of specialized culture microenvironments, including 3D matrices and microperfusion. 
Here, we report an approach to co-culture multiple different MPSs linked together physiologically on 
re-useable, open-system microfluidic platforms that are compatible with the quantitative study of 
a range of compounds, including lipophilic drugs. We describe three different platform designs – “4-
way”, “7-way”, and “10-way” – each accommodating a mixing chamber and up to 4, 7, or 10 MPSs. 
Platforms accommodate multiple different MPS flow configurations, each with internal re-circulation to 
enhance molecular exchange, and feature on-board pneumatically-driven pumps with independently 
programmable flow rates to provide precise control over both intra- and inter-MPS flow partitioning 
and drug distribution. We first developed a 4-MPS system, showing accurate prediction of secreted 
liver protein distribution and 2-week maintenance of phenotypic markers. We then developed 7-MPS 
and 10-MPS platforms, demonstrating reliable, robust operation and maintenance of MPS phenotypic 
function for 3 weeks (7-way) and 4 weeks (10-way) of continuous interaction, as well as PK analysis of 
diclofenac metabolism. This study illustrates several generalizable design and operational principles for 
implementing multi-MPS “physiome-on-a-chip” approaches in drug discovery.
The failure of pre-clinical cell culture and animal models to predict drug safety and efficacy in humans results in 
billions of wasted dollars each year and slows development of treatments for needy patients1–4. These gaps have 
driven an explosion of approaches to capture complex human physiology in vitro, merging several parallel threads 
of science and technology, including pluripotent stem cell (PSC) and organoid biology; design principles and 
tools for 3D tissue and organ culture; microfluidic and mesofluidic approaches to controlling perfusion flow; and 
quantitative systems pharmacology models5. These efforts are driving development of tools often referred to as 
“microphysiological systems” (MPSs) or “organs-on-chips” (OOCs), which encompass the subset of approaches 
employing (i) perfusion flow to improve physiology or workflow even for monolayer cultures of a single cell 
type, and (ii) 3D cultures comprising multiple different cell types, representing a desirable subset of organ or 
1Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. 2Department 
of Mechanical Engineering, Massachusetts Institute of Technology, Cambridge, MA, USA. 3Center for Gynepathology 
Research, Massachusetts Institute of Technology, Cambridge, MA, USA. 4Research Laboratory of Electronics, 
Massachusetts Institute of Technology, Cambridge, MA, USA. 5Continuum LLC, Boston, MA, USA. 6Department 
of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. 7Department of Chemical Engineering, 
Northeastern University, Boston, MA, USA. 8Center for Environmental Health Sciences, Massachusetts Institute of 
Technology, Cambridge, MA, USA. 9Stokes Consulting, Redwood City, CA, USA. 10CnBio Innovations, Hertfordshire, 
United Kingdom. Collin D. Edington and Wen Li Kelly Chen contributed equally to this work. Correspondence and 
requests for materials should be addressed to D.L.T. (email: trumper@mit.edu) or M.C. (email: mcirit@mit.edu) or 
L.G.G. (email: griff@mit.edu)
Received: 9 November 2017
Accepted: 28 February 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIENTIfIC REPORTS |  (2018) 8:4530  | DOI:10.1038/s41598-018-22749-0
tissue functions (e.g. metabolism or excretion), with or without flow through the system, as recently reviewed 
elsewhere6–14. The term MPS is used here, rather than “OOC,” to avoid the implication that an entire organ system 
is recapitulated in vitro.
Applications in pre-clinical pharmacology and toxicology, with an emphasis on drug metabolism and safety 
pharmacology, were arguably the early, highly visible drivers of the field and remain prominent in publications 
and in commercialization efforts6,7,11,15–25. For these applications, design of individual MPSs and interlinked 
multi-MPS platforms has predominantly focused on capturing prominent physiological functions such as 
absorption, metabolism, or barrier function represented by one or two cell types. However, at least two factors 
are driving creation of systems with greater biological (and correspondingly technological) complexity. One is 
the growing recognition that the governing biological phenomena in preclinical pharmacology and toxicology 
often involve multiple cell types with complex mechanistic crosstalk within a single MPS. For example, standard 
hepatocyte-centric in vitro liver models fail to capture the deleterious interplay between the immune-targeting 
drug Tocilizumab and metabolism of small molecule drugs that emerged after Tocilizumab entered the clinic20.
A second important factor driving development of more complex systems is that drug failures mostly arise 
from lack of efficacy, not drug toxicity3. This is especially true of cancer and chronic diseases without clear single 
gene defects, such as diabetes, Alzheimer’s, and arthritis, where multiple organs and tissues may be involved in 
the pathology. Thus, disease modeling, with the aim of evaluating targets and efficacy, is emerging as a prominent 
frontier for the field, driving development of complex MPSs with perfusable microvascular networks and other 
higher-order tissue functions26–28.
In tandem, multi-MPS platforms are evolving to support greater complexity of MPS configurations for analy-
sis of multiple modes of organ-organ crosstalk11,29–36. These platforms bring with them a host of both conceptual 
and technical challenges. Conceptually, the first challenge is framing the physiological problem appropriately – 
the minimal MPS compositions and formats needed to determine clearance of a small molecule drug are rarely 
the same as those needed for biological therapeutics, for example, and efficacy evaluations are all unique. Second, 
scaling MPSs (tissue:tissue and tissue:media ratios) to obtain adequate in vitro-in vivo translation (IVIVT) 
remains a challenge without a universal solution. The most common scaling approaches are direct miniaturization 
and allometric scaling37–40. However, an alternative scaling approach, rooted mechanistically in the functional 
aspects of each MPS in an application-based context, may provide more versatility to accommodate the diversity 
of applications and range of experimental constraints encountered in multi-MPS platform implementation41.
Technical challenges in building functional multi-MPS platforms include: (i) creation and maintenance 
of MPSs that exhibit sufficiently representative and robust physiological function over extended culture peri-
ods, typically requiring resource-intensive procurement and preparation of primary cells or pluripotent-stem 
cells (PSCs) to reach functional maturity in specialized microenvironments; (ii) design and fabrication of plat-
form hardware that can accommodate and sustain the relevant MPSs – including transfer from off-platform to 
on-platform for MPSs requiring disparate maturation times and complex maturation media – while fluidically 
linking them together in a manner that is permissive for quantitative analysis of biological phenomena involving 
drug fate or disease phenomena; (iii) selection of a medium composition compatible with the different MPSs 
on the platform; (iv) a variety of other practical and translational aspects including flow partitioning, flow rates, 
physiological sensors, sampling frequency, and sample volume, among others.
Here, we describe the development and implementation of multi-MPS platforms, aka physiome-on-a-chip, 
supporting 4-way, 7-way, and 10-way MPS interactions for several weeks in the context of these conceptual and 
technical challenges, illustrated in Fig. 1. We focus on pharmacological testing and interrogation of MPS cross-
talk, thus illustrating the use of quantitative systems pharmacology (QSP) modeling for integrating experimental 
design and interpretation with platform design and operation. QSP was originally defined as a combined exper-
imental and computational approach in translational medicine to elucidate and apply pharmacological concepts 
for development and use of therapeutics42, but has recently been extended to the development of multi-MPS 
technologies5,38. The empirical pharmacokinetic and pharmacodynamic (PKPD) models currently used to char-
acterize relationships between drug kinetics and biological effects in in vivo models are not directly translatable 
to multi-MPS platforms; rather, the diversity of MPS designs requires the use of PKPD models that include more 
mechanistic details that capture the interrelated physical dynamics (e.g., flow rates in the MPS) and biological 
dynamics (e.g., drug metabolism and transport, cytokine/growth factor/hormone production and release) in 
order to select the appropriate experimental conditions, analyze results, and predict human outcomes30,43. QSP 
experimental design takes into account cell numbers and types in each MPS, working media volumes, and flow 
patterns (flow-through or closed circuit) among different MPS configurations, and involves characterization of 
the relationships between drug exposure and MPS responses. The flow partitioning between MPSs and total 
systemic flowrate, together with MPS configuration (i.e., diffusional or other molecular transport barriers within 
each MPS) are the operational drivers of drug exposure in each MPS38.
The platforms developed and characterized in this work (Fig. 1) derive from the open system, multi-well plate 
format utilized in Liverchip® technology, which we developed for long-term perfused culture of 3D liver-like 
tissue44,45 and recently extended to 2-way (gut-liver) MPS pharmacokinetics36 and inflammation30 interactions. 
These new platforms incorporate a high degree-of-freedom (DOF) on-board pumping system with a wide range 
of flow rates and low drug binding to precisely control intra- and inter-MPS mixing and distribution. This tech-
nology enables simultaneous tuning of flow rates between and within different MPSs in a circulation loop, a fea-
ture missing in most active and passive fluid-control systems that have been implemented in multi-MPS systems.
Features of the Liverchip® design retained in this multi-MPS platform are an open-system format constructed 
with materials refractory to adsorption of lipophilic drugs and hormones and sufficient pumping capacity to 
support modeling of diseases such as cancer metastasis46, where relatively large (1 + million cells) tissue mass 
is required in each MPS. The platforms accommodate a mixing chamber (“mixer”) for the systemic circula-
tion, a liver module that recirculates flow through a scaffold with 3D primary human liver culture, and up to 
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nine Transwell®-format MPS modules with recirculation in the basal compartment. The Transwell® MPS for-
mat is attractive for barrier epithelial tissues such as gut, lung, and others, as many established and emerging 
protocols for constructing intact epithelial barriers exhibiting varying degrees of physiological permeability and 
excretion have been described using off-the-shelf components. They can be constructed off-platform and moved 
on-platform at appropriate stage of maturity31,47,48. Models of the central nervous system (CNS) and other tissues 
and organs have also been adapted to a Transwell® format amenable for inclusion on this platform22,49.
In the first system, we demonstrate two-week sustained functional maintenance of four interacting MPSs 
(liver/immune, lung, gut/immune, and endometrium). Using stepwise escalation of the flow rates on the 4-way 
platform we then show that systemic distribution of secreted proteins follows a predictable profile as the system 
approaches a more rapidly well-mixed state. Next, we demonstrate the first reported co-culture of seven inter-
acting MPSs. This system, consisting of an additional three MPS (brain, heart, and pancreas) to the first four, 
was able to maintain phenotypically functional cultures for 3 weeks of interaction. Using this 7-way platform, 
we quantified in vitro pharmacokinetics of diclofenac, a non-steroidal anti-inflammatory drug, given as an “oral” 
dose to the apical side of the gut barrier epithelium. We found strong agreement between the computationally 
predicted and measured concentrations of the drug and its metabolite in the system.
Finally, a 10-way MPS platform was configured to include kidney, skin, and skeletal muscle MPSs, in addition 
to the 7 MPSs described above. The 10-way platform was successfully operated in continuous interaction mode 
to maintain MPS phenotypic functionality for 4 weeks. Notably, successful operation of this platform relied on 
robust performance of all 26 individual pumps for almost 5 weeks (including pre-interaction set-up), and design 
features that minimized risk of contamination during handling, including medium changes and acquisition of 
over ~1200 fluid samples from the MPS compartments and mixing chamber.
Together, these data support the effectiveness of our approach to multi-MPS experiments using integrated 
pumping hardware and QSP to enable high-content biology studies for clinically translatable applications in 
preclinical drug discovery and development. The robustness of the approach to long-term co-culture and analysis 
of multiple interacting MPSs in a reconfigurable arrangement (as demonstrated by the iterative development of 
4-way, 7-way, and 10-way designs) is also appealing for non-commercial applications involving complex biolog-
ical responses. Although multi-MPS platforms have sometimes been called “human-on-a-chip”, we prefer the 
term “physiome-on-a-chip” to describe integration of multi-MPS hardware with QSP-type modeling. Even with 
Figure 1. Schematic overview of Physiome-on-a-chip approach. The Physiome-on-a-Chip comprises 
bioengineered devices that nurture many interconnected 3D MPSs representing specified functional behaviors 
of each organ of interest, designed to capture essential features of in vivo physiology based on quantitative 
systems models tailored for individual applications such as drug fate or disease modeling. By interconnecting 
MPSs, dynamic multi-organ signaling can be recreated naturally through cytokine and hormone circulation, 
cell trafficking, and metabolic byproducts. Multi-MPS systems bridge the complexity gap between traditional 
in-vitro cell culture, animal models, and human patient samples, potentially providing better prediction of 
human responses at lower financial and ethical costs as compared to current methods of drug development. 
Illustration by Victor O. Leshyk.
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10 MPSs, our platform falls short of replicating an entire human, and requires QSP modeling for conceptualizing 
the relevant physiology and interpreting experimental results.
Results
Multi-MPS platform design and fabrication. Several desired features of the multi-MPS platform were 
integrated to define the hardware design. An envisioned application of the multi-MPS platform described here is 
examination of molecular crosstalk between MPSs via cytokines, growth factors, and other molecular communi-
cation modes. This consideration drove an open-system hardware design that allowed relatively straightforward 
manual sampling of the systemic medium locally within each MPS compartment. An open system also facilitated 
internal recirculation loops within each MPS to ensure adequate mixing (i.e. in the basal Transwell® compart-
ment or in the flow-through microperfused liver) at internal recirculation rates about 10–100 times greater than 
flow rates between different MPSs (Figs 2, S1 and S2, Table S1). For epithelial barrier tissues (e.g. gut, endome-
trium, lung), separately accessible apical and basal compartments, with an intact epithelial barrier that could be 
characterized periodically by trans-epithelial electrical resistance (TEER), was desired, leading to selection of 
off-the-shelf Transwell®-style configurations. For liver, previous work20,44,50–52 suggested that 3D cultures perform 
better for functional maintenance, with a flow-through microperfusion of the 3D tissue to enhance local exchange 
of oxygen, nutrients, and drugs independently of systemic circulation rates; hence, the previously developed 
Liverchip® design was adopted (see below).
Unlike epithelial barrier tissues, there are no standardized MPS formats for the non-barrier MPSs (brain, 
pancreas, heart, muscle). The use of separate high-capacity recirculation pumps for each MPS enables either a 
flow-through or a Transwell® format to be assigned at the time of fabrication. For the 7-way platform, a published 
Figure 2. MPS platforms and their flow partitioning. Exploded rendering of the 7-MPS platform (a) and 
corresponding flow partitioning for the 7-way platform (b). Rigid plates of polysulfone (yellow) and acrylic 
(clear) sandwich an elastomeric polyurethane membrane to form a pumping manifold with integrated fluid 
channels (See Fig. S2 for pump details). Channels interface to the top side of the polysulfone plate (yellow) to 
deliver fluid to each MPS compartment in a defined manner. Fluid return occurs passively via spillway channels 
machined into the top plate (See Fig. S2 for details). Flow partitioning mirrors physiological cardiac output for 
the 4-way (b), 7-way (c) and 10-way (d) platforms. Renderings for the 4-way and 10-way platforms are shown in 
Fig. S1.
www.nature.com/scientificreports/
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Transwell®-format brain module22 was adopted, and a Transwell® module was similarly deployed for the heart 
and all additional modules on the 10-way platform. A flow-through module (identical to the liver MPS) was 
adopted for pancreas on the 7-way platform. Although these design considerations resulted in medium volumes 
and tissue ratios different than those considered elsewhere37,39,53, the QSP modeling approaches employed here 
incorporate the operational characteristics of each MPS in a mechanistic manner to design interaction exper-
iments and data interpretation. Such considerations include the ways in which MPSs carry out physiological 
functions relevant for the applications, accounting for fluid flow rates and molecular exchange rates, and incorpo-
rating intrinsic rates of consumption or production of compounds by relevant cell types in the MPSs.
The multi-MPS fluidic platform used for N-way interactions is a micro-machined bioreactor device with a 
form factor similar to a microtiter plate, and is built in 3 layers: a top (fluidic) plate, a flexible membrane layer, 
and a bottom (pneumatic) plate. Expanded renderings of the 4-, 7-, and 10-MPS platforms are shown in Figs 2 
and S1. Details of the pumping and fluidics are depicted in Fig. S2. The top layer is machined from a monolithic 
block of polysulfone (PSF) plastic and includes compartments to accommodate each MPS plus an extra chamber 
to integrate and mix return flows (mixer), representing systemic circulation. Any remaining space on the top sur-
face can be machined to create a water reservoir to increase local humidity and limit evaporation from the culture 
medium. Microfluidic channels and pumps are machined into the underside of the top plate and convey fluid 
from the mixing chamber to each MPS. The individually addressable micro-pumps are fabricated in-line with the 
fluid channels and are based on the 3-chamber, positive displacement design previously described45 and shown in 
more detail in Fig. S2. Additional pumps below each MPS compartment provide recirculation flow to mix media 
within the MPS (Fig. S2, Table S1), enhancing nutrient and oxygen transport, and allowing intra-MPS mixing to 
be controlled independently from the overall systemic recirculation (mixing) rate.
Fluid return and self-leveling of MPS wells are achieved passively by a system of spillway channels on the 
top surface of the plate that deliver medium back to the mixer (Fig. S2). Spillways eliminate the need for return 
pumps and level sensors to enforce a balance between influx and efflux while also allowing return flows to cross 
feed flows in a separate plane. The clear acrylic bottom plate serves as a pneumatic manifold to deliver pressur-
ized air and vacuum locally to each pump, and is bolted to the top plate with screws and spring washers to evenly 
distribute load. Clamped between the two plates, a thin polyurethane membrane forms the actuation layer and 
seals the pumps and channels.
The multi-MPS platform operates with multiple pneumatic lines, each of which can be independently set to 
a pressure or vacuum state (typically +/− 40 kPa), and therefore represents one DOF for fluid control. A single 
DOF can be used to actuate a valve, while 3 DOF can be used in concert to create a positive displacement pump 
by actuating two valves and a central pump chamber. Although each individually addressable pump requires 3 
DOF, multiple pumps can be run at the same rate by sharing inlets on the pneumatic manifold allowing many 
pumps to be driven by one triplet of pneumatic lines. Using such a parallel configuration reduces the number 
of pneumatic switching valves needed in the controller as well as the number of pneumatic tubes entering the 
incubator. The 4-MPS platform has 9 pumps with 6 separately-programmable flow rates (18 DOF), whereas the 
7-MPS platform has 17 pumps with 12 separately-programmable flow rates (36 DOF). The 10 MPS platform 
also has 12 separately-programmable flow rates (36 DOF), associated with 26 pumps. Greater parallelism in the 
10-MPS platform allowed reuse of the same controller as in the 7-MPS platform.
The platforms all accommodate two MPS formats, either flow-through modules or standard Transwell® 
inserts, and contain a central mixing module downstream of all MPS compartments. The flow-through module 
format is similar to that previously described, in which on-board pneumatically-actuated microfluidic pumping 
is used to perfuse culture medium through a scaffold supporting an array of individual 3D liver tissue-like aggre-
gates, such that a near-physiological drop in oxygen tension occurs across the tissue52. The scaffold is maintained 
in a recirculation loop that passes low-oxygen medium across a shallow, open channel, thus providing adequate 
re-oxygenation before the media returns to the scaffold. Specifications for each MPS configuration and volumes, 
as well as total system volumes, are in Table S1. Finally, the ergonomics of the platform during handling and 
sampling were evaluated iteratively throughout the design process to ensure ease of use and to minimize risk of 
contamination (see Supplemental Video 1).
Platform Fluidic Performance. To enable effective mixing on the platform and predictable molecular bio-
distribution among MPSs, it is critical to ensure parity between the intended and actual flow rates as well as high 
reliability of the individual pumps, as failure of a single pump compromises the entire platform function. Initial 
characterization of the hardware included direct measurements of pump rates using a capillary tool with a known 
diameter. Measurements of the height change per unit time give the flow rate. When targeting a flow rate of 
1 µL/s (2 Hz), flow rates in thirteen 4-MPS platforms (n = 9 pumps per platform) averaged 0.92 µL/s ± 0.12 µL/s 
(Fig. S3a). Flow rates in ten 7-MPS platforms (n = 17 pumps per platform) averaged 1.12 ± 0.10 µL/s (Fig. S3b). 
These deviations are likely attributable to slight machining differences in the depth of the pump chamber. We 
found that software calibration factors, calculated from an initial measurement, can correct the pump rates to 
within ±5% of the target flow rates (0.99 ± 0.056 µL/s, Fig. S3c). In practice, we found this low margin of error 
allows for reliable and deterministic operation, and hence accurate data interpretation. Platforms were stress 
tested by running all pumps at 2 Hz continuously for ~6 weeks (7.2 million cycles). Final flow rates were found to 
be within 10% of initial values and no membrane damage was found upon visual inspection. Flow rates for the 10 
pairs of plates comprising the 10-MPS systems were found to perform in a similar manner to the 4- and 7-MPS 
systems (Supplemental Fig. S3d).
Maintenance of long-term functionality of interconnected MPS. Prior to assessing responses to 
interventions, the functional behavior of MPSs in interaction was characterized over time periods of up to 2 
weeks (4-way platform), 3 weeks (7-way), and 4 weeks (10-way). The 4-MPS platform studies included liver, gut, 
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lung, and endometrium MPSs, whereas 7-MPS experiments added models for brain, heart, and pancreas MPSs. 
The 10-way included an additional three systems: skin, kidney, and skeletal muscle MPSs. With the exception 
of the liver, which was established on platform 3 days before the start of the interaction experiments, all MPSs 
were matured off-platform and transferred on-platform on the first day of interaction. Cells used in the various 
MPSs derived from primary sources (liver, lung, pancreas, skin, skeletal muscle, kidney, immune cells in gut and 
liver), PSCs (heart, brain) and cell lines (endometrium, gut) with different medium needs, and thus no common 
medium was defined a priori. Each MPS was established on the platform in its respective maintenance culture 
medium at the start of the interaction experiment. During most multi-MPS studies, a systemic interaction flow 
rate (Qsys) of 5 mL/day, 10 mL/day, or 20 mL/day (rates that exchange 60%, 80% and 110% of total system volume 
per day) for 4-, 7- and 10-MPS studies, respectively, was partitioned to each MPS from the mixer based on the 
relative percentages of cardiac output to each tissue type in humans (as shown in Fig. 2). Intra-MPS recirculation 
rates listed in Table S1 were used to enhance mixing; these numbers can be easily modified in the control soft-
ware for different scaling strategies and MPS modules. Complete media changes were conducted every 48 hours 
(replacing each MPS’s particular maintenance medium), during which samples were taken to measure secreted 
biomarker concentration from each MPS, as well as TEER and beat frequency where applicable. Continuous 
functionality metrics from 4-MPS, 7-MPS and 10-MPS studies are shown in Figs 3, 4 and 5, respectively. In paral-
lel, the functionality of each type of MPS maintained in isolated culture was monitored (Figs S4–S6).
In the 4-MPS interaction study (2-week duration) albumin secretion showed a transient increase in the first 
few days, followed by a gradual return to initial levels (Fig. 3). Barrier integrity of the gut/immune and lung 
MPSs was quantified with TEER. TEER values from the gut/immune MPS fluctuated in the early days of interac-
tion studies before settling into a 150–250 Ω · cm2 range for the remainder of the experiment. Lung MPS TEER 
values followed a similar trend of high TEER during the first few days, but eventually established stable values 
in the 600–800 Ω · cm2 range. Endometrium MPS functionality, evaluated by secretion of insulin-like growth 
factor-binding protein 1 (IGFBP-1), remained around 20–30 pg/day throughout the study. Similar trends for each 
phenotypic metric were observed in the isolation studies, except IGFBP-1 secretion rate, which was lower in the 
isolated endometrium MPS (4–12 pg/day) than during interaction studies (20–30 pg/day).
Next, biological compatibility of 7 MPSs (gut/immune, liver/immune, lung, endometrium, heart, brain 
and pancreas) was assessed in interaction over a 3-week period (Fig. 4). Again, each MPS was differentiated or 
Figure 3. Assessment of MPS functionality in 4-MPS platform. Metrics of tissue function measured during 
a 2-week co-culture of 4 different MPSs. MPS representing liver, gut, lung, and endometrium were linked 
using the platform and flow scheme and partitioning shown in Fig. 2. Samples collected from each platform 
compartment were used to measure protein and metabolite concentrations, which were in turn used to 
calculate production rates via computational PBPK models. Albumin secretion rates were used as an indicator 
of liver function (a). Barrier functions of gut (b) and lung (c) MPSs were assessed with TEER measurements. 
Endometrium MPS functionality was characterized with IGFBP-1 secretion rate to its apical medium (d). 
Compartment and system volumes are in Table S1. The systemic exchange flow rate Qsys was 5 mL/day.
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matured in isolation prior to the interaction study and operated with flow partitioning as shown in Fig. 2. Similar 
to 4-MPS results, we observed transients in albumin secretion kinetics (with stabilization after a week in this 
case), sustained gut and lung TEER values, and IGFBP-1 secretion. The beat frequency associated with cardiac 
muscle cells was used as a functional metric for the heart MPS. We observed that beat frequency was robustly 
maintained between 45–50 beats/min except for a transient increase to 60–66 beats/min on day 8. N-acetyl 
aspartate (NAA) and c-peptide release profiles, metabolic indicators of neuron and pancreatic beta cell activity, 
respectively, revealed that both the brain MPS and the pancreas MPS were also functional for 3 weeks of culture. 
Comparison of the interaction results with the isolation results showed no negative effect of interaction on the 
MPS functionality. On the contrary, we observed enhanced NAA (brain) and c-peptide (pancreas) production 
during the interaction. Due to a dramatic reduction in pancreas MPS functionality in the “isolation” study arm, 
islets were replaced at day 12 for both interaction and in isolation study arms.
Lastly, 10 MPSs (gut/immune, liver/immune, lung, endometrium, heart, brain, pancreas, kidney, skeletal 
muscle and skin) were interconnected and the functionality of each MPS was assessed over 4 weeks (Fig. 5). 
As described above, each MPS was differentiated or matured in isolation prior to the interaction experiment. 
Similar to our 4- and 7-MPS interaction studies, albumin secretion kinetics was transient. Gut and lung MPS 
TEER values and trends, IGFBP-1 secretion by the endometrium MPS, and heart beat rate were comparable 
among interaction studies. In this particular study, unlike the 7-MPS interaction study, the brain MPS comprised 
iPSC-derived neurons. NAA secretion profile was again sustained and enhanced compared to the isolation study. 
Figure 4. Assessment of MPS functionality in 7-MPS platform. Metrics of tissue function measured for 3-week 
co-culture of 7 different MPS. MPS representing liver, gut, lung, endometrium, heart, pancreas, and brain 
were interconnected using the platform, and flow scheme and partitioning shown in Fig. 2 with system and 
individual compartment volumes indicated in Table S1. Samples collected from each platform compartment 
were used to measure protein and metabolite concentrations, which were in turn used to calculate production 
rates via computational PBPK models. Albumin secretion rates were used as an indicator of liver function (a). 
Barrier functions of gut (b) and lung (c) MPSs were assessed with TEER measurements. Endometrium MPS 
functionality was characterized with IGFBP-1 secretion rate (d) to its apical medium. Heart MPS function 
was evaluated with beat frequency (e). C-peptide production rates (f) represented pancreas function. N-acetyl 
aspartate (NAA) concentrations (g) in the apical brain MPS indicated brain MPS functionality. The systemic 
exchange flow rate Qsys was 10 mL/day.
www.nature.com/scientificreports/
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The pancreas MPS was modified for this study, and 25 islets per MPS were added in a Transwell® format. The 
observed c-peptide production kinetics were comparable with results from the 7-MPS platform. The barrier func-
tion of the kidney MPS, as monitored by TEER, was maintained throughout the experiment, although the TEER 
Figure 5. Assessment of MPS functionality in 10-MPS platform. Metrics of tissue function measured for 
4-week co-culture of 10 different MPS. MPS representing liver, gut, lung, endometrium, heart, pancreas, brain, 
skin, kidney, and skeletal muscle were interconnected using the platform, and flow scheme and partitioning 
shown in Fig. 2 with system and individual compartment volumes indicated in Table S1. Samples collected 
from each platform compartment were used to measure protein and metabolite concentrations, which were in 
turn used to calculate production rates via computational PBPK models. Albumin secretion rates were used 
as an indicator of liver function (a). Barrier functions of gut (b) and lung (c) MPSs were assessed with TEER 
measurements. Endometrium MPS functionality was characterized with IGFBP-1 secretion rate (d) to its apical 
medium. Heart MPS function was evaluated with beat frequency (e). C-peptide production rates (f) represented 
pancreas function. N-acetyl aspartate (NAA) concentrations (g) in the apical brain MPS indicated brain MPS 
functionality. Barrier functions of skin (h) and kidney (i) MPSs were assessed with TEER measurements. 
Myostatin secretion was used as an indicator of skeletal muscle function (j). The system exchange flow rate Qsys 
was 20 mL/day.
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values from the interaction study were 3-fold lower than those from isolation studies. Muscle MPS functionality 
was assessed by myostatin secretion, a myokine released by myocytes, and was well maintained up to day 22, 
after which secretion decreased during the later stages of the interaction. Barrier function of the skin MPS was 
transient for both interaction and isolation studies, which suggested the drop in TEER was not due to interaction 
effects. Thus, the skin MPS was replaced at day 14 with a new skin MPS from a new donor. Similarly, a decline in 
dendritic cell number, as expected based on their natural half-life54, led us to reseed those cells onto the gut MPS 
on day 19 as described in Methods.
In summary, these findings demonstrated that long-term MPS viability and functionality were maintained in 
the 4-, 7-, and 10-MPS platforms for applications requiring extended culture periods of up to four weeks.
Endogenous and exogenous molecular distribution in the multi-MPS platforms. Deterministic 
operation of multi-MPS platforms via high DOF pumping schemes facilitates in vitro data interpretation and 
translation to in vivo outcomes. After establishing that the platforms were mechanically reliable and could sup-
port multi-MPS interactions, we investigated the molecular distribution and quantitative measurement of a drug 
and its metabolite using an integrative approach of quantitative molecular characterization and QSP models.
In the 4-MPS platform, the effect of systemic flowrate (Qsys) on the distribution kinetics of endogenously-produced 
albumin was characterized by collecting samples from each compartment every 48 hours during the medium 
change and analyzing the results with PBPK computational models (Supplementary Methods). A comparison 
of the albumin concentrations for the experimental measurements and PBPK models of the data in the mixing 
chamber and each MPS compartment at day 2 (Qsys = 5 ml/day, exchange rate 0.6 × total system volume per day), 
day 4 (Qsys = 15 ml/day, 1.9 × total system volume per day), and day 6 (Qsys = 30 ml/day, 3.8 × total system volume 
per day) are presented in Fig. 6. Not surprisingly, with increasing systemic flow rate, albumin is distributed more 
uniformly among MPSs on the 4-way platform. Interestingly, this flow-escalation experiment also illuminates 
that increasing the systemic exchange rate to ~4 total volume exchanges per day does not appear to adversely 
affect liver function significantly, as the inferred albumin secretion rates do not change with increased systemic 
medium exchange rates.
As a case study to demonstrate applicability of the platform and QSP framework to pharmacology, we inves-
tigated diclofenac (DCF) in vitro pharmacokinetics in the 7-MPS platform. First, PBPK model simulations (data 
not shown) of DCF distribution across MPSs –incorporating planned operational parameters (MPS volumes, 
flowrates) and previously measured values of DCF clearance (liver) and permeability (gut) in isolated MPSs – 
were used to predict that a DCF dose of 60 uM applied to the apical gut MPS (mimicking oral administration) 
would achieve a Cmax in the platform mixer similar to that measured clinically (2–6 µM55). The experimentally 
observed media concentrations of DCF and its metabolite 4-OH-DCF in each MPS compartment (at 48 hours) 
and the mixing chamber (at 24 and 48 hours) following administration of this dose are illustrated in Fig. 7 (sym-
bols); continuous model simulations for the entire 48 hours are shown with curves. The simulated curves resulted 
from the same model used to select dose, but instead of using clearance parameters from isolated liver MPS exper-
iments we estimated values of DCF unbound intrinsic clearance and fraction of metabolism giving 4-OH-DCF 
specific for this experiment by fitting all 57 measured data points simultaneously. All other model parameters 
were fixed at experiment values (Table S3). As seen by following the magnitude and dynamics of distribution 
across the platform, the characteristics of the measured concentrations in each compartment are consistent with 
predictions of the PBPK model: the 60 µM initial concentration of DCF on the apical side of the gut resulted in 
a transient increase in the basal compartment to ~11 µM at 15 hr, which propagates to a transient increase in 
the liver to about 4 µM, followed by decline to the measured value of 2 µM by 48 hr as the concentration of the 
metabolite 4-OH-DCF increases. In turn, the mixer, just downstream of the liver, shows a peak of ~2 µM at 24 hr, 
consistent with our desired Cmax, then a slow decline over the next 24 hr as DCF is converted to 4-OH-DCF. The 
concentrations in the downstream MPSs rise later, with all MPS media approaching a similar concentration by 
the 48 hr endpoint as the media becomes more well-mixed during the experiment. The 4-OH-DCF metabolite, 
Figure 6. Escalation of systemic flow rate in 4-MPS platform enhances molecular exchange between MPSs 
without apparent alteration of MPS functionality. Measurements of the concentration of human serum albumin 
(produced by the liver MPS; red dots) and QSP model fits to the experimental data (Whisker plot indicating 
median, min-max values) for the mixer and for each individual MPS (liver, lung, endometrium, and gut) for 
baseline systemic flow rate Qsys = 5 ml/day (left panel) and increased systemic flow rates of Qsys = 15 ml/day 
(middle panel) and Qsys = 30 ml/day (right panel). The total production rate of albumin is not affected by the 
flow escalation.
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which is produced by cytochrome p450 enzymes present mainly in the liver MPS, circulated throughout the 
7-MPS platform and was detected in all the other MPS compartments. The DCF unbound intrinsic clearance 
(CLint(u)) referring to hepatic metabolism was estimated to be 13.9 µL/min and approximately 19% of this clear-
ance was estimated as formation of the 4-OH-DCF metabolite (the rest towards other, unmeasured, metabolites).
Discussion
A range of different multi-MPS platform technologies are emerging to address the increasing need for analysis 
of complex human physiological responses in a controlled in vitro format, for applications ranging from disease 
modeling to testing efficacy and safety of therapeutic interventions30–36,53,56,57. The major contributions of the work 
presented here include a novel combination of platform performance attributes and integration techniques, func-
tional longevity of up to 10 complex interacting MPSs, and demonstration of how QSP computational approaches 
can be combined with platform technologies to model distribution of both endogenously-produced molecules as 
well as in vitro pharmacokinetics. Together, the results provide a foundation for applying this platform to aspects 
of disease modeling where inter-MPS communication between a variety of different types of MPS constructs is 
needed, especially for long-term (weeks) culture experiments.
This platform combines several performance features in a novel manner, including: open system architecture; 
on-board, programmable and reconfigurable pumping that combines high flow rate capacity (0.05–300 uL/min), 
high DOF, and reliability over weeks of operation; relatively inert materials of construction; ability to accept 
off-the-shelf standard MPS constructs as well as custom designs; and standard multi-well plate footprint for use 
in standard incubators. Many current multi-MPS systems employ a closed-system fluidic format associated with 
traditional microfluidic chips, which operate in linear or circular flow schemes with very small fluid volumes, 
can have cost advantages when using expensive cells or reagents, and are amenable to in situ imaging and pro-
ducing physiological shear rates on cell monolayers35,58–60. Closed-system microfluidic single- and multi-MPS 
Figure 7. Quantification of diclofenac pharmacokinetics in 7-MPS platform. Samples for diclofenac (DCF) PK 
were collected from each compartment and quantified for parent drug (DCF, black symbols) and its primary 
metabolite (4-OH-DCF, red symbols). Individual points represent measurements from different platforms. 
The results were analyzed with PBPK models, illustrated by solid curves spanning the 48-hour experimental 
duration.
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platforms are commonly fabricated from PDMS34,61–63 as it has excellent oxygen transport, optical clarity, and pro-
totyping properties, but also undesirable drug partitioning and hormone adsorption properties64–66. The draw-
backs of PDMS have stimulated fabrication of MPS microfluidic platforms from materials more favorable for 
quantitative pharmacology applications32,56,67,68 with tradeoffs in reduced oxygen transport for supporting highly 
metabolically-active MPSs. Surface-modification approaches to reduce absorption of drugs into PDMS devices 
have also been described as successful in some implementations, though the strong tendency of PDMS for surface 
rearrangement can limit the length of time surface modification remains effective65,66.
Open microfluidics systems are a less common format, but design principles for these systems are emerging69 
as they offer several advantages. Because gas exchange can occur at the air-liquid interface in an open system, the 
platform material itself does not need to be oxygen permeable. We built the fluid handling portion of the plat-
form from polysulfone (PSF), a rigid, amber colored, machinable thermoplastic with food grade FDA approval 
(21CFR177.1655) and USP Class VI biocompatibility. Polysulfone is resistant to a wide range of chemical sol-
vents, can be autoclaved, and is commonly used for instrumentation and medical devices. Polysulfone has dra-
matically lower surface adsorption and no bulk absorption of hydrophobic and lipophilic compounds, compared 
to elastomers like PDMS70.
Moreover, in the open system format, the various MPSs are highly modular and can easily be changed during 
operation, allowing replacement of individual MPSs as part of planned experimental protocols, e.g., to study 
effects of a “diseased” MPS (such as fatty liver) on “healthy” MPSs (or vice versa), or to do an “MPS transplant” 
to replace an MPS damaged by a perturbation (e.g. drug treatment) in an otherwise healthy platform. This fea-
ture was demonstrated in the 7-way experiments, where the pancreas MPS was replaced after 12 days based on 
prior data from static (off-platform) MPSs indicating decline of function over this time; subsequent analysis of 
c-peptide production indicated the on-platform performance of the pancreas MPS exceeded that of static culture 
by this metric. The open system format also allows access to all MPS compartments (e.g. apical and basal gut com-
partments) for manual or robotic fluid sampling and in situ measurements (e.g. TEER, imaging beat frequency) 
throughout operation. In addition, linking between MPSs does not have to be linear or circular, which, as noted, 
is an inherent limitation of many closed systems. The open system platform designs described here are also highly 
robust toward maintenance of sterility during operation and handling, as evidenced by continuous operation 
for over 4 weeks (i.e., the 4 weeks of co-culture and additional pre-culture of the liver compartment), including 
handling for collection of >1200 individual fluid samples.
An especially important feature of this multi-MPS platform is the incorporation of a high DOF, high capacity, 
long-lifetime on-board pumping system. On-board pumping saves dramatically on space and cost compared 
to commercial syringe or peristaltic pumps (e.g., the 7-MPS system has 36 DOF which operate the functional 
equivalent of 17 syringe pumps per platform), is more scalable, and allows systemic recirculation operation with 
low dead volumes (<1% of total volume). Each pump has a capacity of 0.05–300 µL/min and operates at initial 
calibration values over millions of cycles, with reliable function for at least 4.5 weeks as shown in the 10-way 
experiment.
This high DOF enables internal MPS recirculation flow rates, which govern oxygenation and local molecular 
transport within each MPS, to be uncoupled from flow rates associated with systemic exchange between MPSs 
in the recirculation loop connecting the MPSs together. Thus, in the liver compartment, internal mixing con-
tinuously perfuses medium through a scaffold containing an array of microscale 3D liver tissue, replicating the 
conditions used in Liverchip® to measure drug PK, maintain an appropriate oxygen tension drop across the tis-
sue, and support disease models20,43,46,52,71. Similarly, internal MPS recirculation facilitates mixing and molecular 
transport at the base of Transwell® MPSs such as the gut/immune MPS. This deterministic mode of pumping, 
combined with mechanism-based QSP models, can enable accurate analysis and prediction of of endogenous and 
exogenous compound distribution. High DOF control also makes it easy to reconfigure this platform for new 
MPSs in either Transwell® or microperfused (i.e., Liverchip®-like) formats as demonstrated by incorporation of 
the flow-through pancreas model on the 7-way. We have also shown the ability to dynamically exclude wells and 
change total system volume by using our 4-MPS platform for 2-MPS gut-liver interaction studies30,36. This high 
DOF pumping scheme with internal MPS recirculation distinguishes the platform described here from other 
multi-MPS platforms, which do not appear to have internal MPS recirculation pumps in addition to systemic 
exchange31,33–35.
The ultimate performance of any multi-MPS platform relies on the functional behavior of individual MPSs 
contributing to the integrated circuit. Arguably, one of the greatest challenges in the MPS field is “validation” of 
individual MPS functionalities and establishing reproducibility of MPS functions by different groups of inves-
tigators. Cell sources (e.g. primary postnatal, iPS-derived, or immortalized cell lines, homotypic vs heterotypic 
culture), physical microenvironment (ECM, 2D vs 3D, scaffold properties, mechanical forces), culture media, 
and device design (molecular transport, oxygenation, etc) all influence the performance of an individual MPS 
for a given application – and for any given MPS, multiple applications often exist, each with their own perfor-
mance metrics. We thus designed this multi-MPS platform to accept two types of commercially-available MPS 
formats: Transwells® and LiverChip®. As for several of the MPS categories included in the work, well-established 
MPS protocols for these standard formats could be imported to the platform for these proof-of-principle studies 
involving several existing MPS categories, and these formats were amenable to creation of functional MPSs in 
other categories. We also employed QSP to design experiments and interpret data, as QSP can account for varia-
tions in operational differences of individual MPSs, such as changes in volume and flow partitioning.
The liver MPS offers an illustrative case for functional scaling via QSP. The large diversity of intrinsic meta-
bolic capacity in vitro for different published liver MPSs underscores the challenges in scaling multi-MPS interac-
tions based on relative in vivo tissue masses or cell numbers, and motivates our analysis by QSP approaches that 
take into account these intrinsic variations. Here, we used commercially-sourced primary human cryopreserved 
hepatocytes and Kupffer cells cultured in a 3D, microperfused MPS modeled after the Liverchip®, as our lab 
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and other laboratories have demonstrated that this format fosters retention of hepatic metabolic and secretory 
functions over weeks in culture. Moreover, this microperfused liver MPS has been well-characterized for drug 
PK and hormone kinetics using multiple drugs and donors20,43,46,52,71, and it has also been extended to gut-liver 
interactions30,36. However, within a given culture configuration, primary human hepatocytes from different 
donors exhibit quite significant variations in drug metabolism rates20,43,72,73. Further, connection to a gut/immune 
MPS30,36 or inflammation20 alters CYP450 activity of primary human hepatocyte-Kupffer cell co-cultures. Other 
higher-order multi-MPS platforms used HepG2/C3A in monolayer culture, iPS- derived hepatocytes, the HeparG 
hepatocyte cell line co-cultured stellate cells in spheroids, and primary human hepatocytes co-cultured with stel-
late cells and Kupffer cells31,33–35, but experimental reports of quantitative drug metabolism rates and in vitro-in 
vivo translation are as yet not available for these systems. Hepatocellular CYP450 expression and activity is typi-
cally much lower in 2D culture than 3D culture44,50,74; however, diffusion limitations can lower apparent metabolic 
rates in both 2D75 and 3D culture44. These variations in donor cell metabolic activity, configurational, and opera-
tional factors all together motivate the QSP approach, which takes such variations into account.
A similar analysis of how to assess performance of all the other MPSs from the perspective of scaling is beyond 
the scope of this discussion, but observations about performance of a few particular MPSs highlight some of the 
additional issues and noteworthy findings from this work. The brain MPS used in the 7-way was adopted from 
protocols developed by the Thomson and Murphy labs at University of Wisconsin, Madison22, with laboratory 
exchanges confirming that comparable results for performance metrics were obtained in the two different geo-
graphic locations. This outcome is arguably an important confirmation of reproducibility across independent 
laboratories and geographic locations. Interestingly, the brain MPS exhibited improved performance metrics 
during interaction on the platform compared to isolation as assessed by production of the metabolite NAA. The 
mechanisms underlying this observation are as yet unknown, but may involve enhanced molecular transport or 
factors produced or consumed by other MPSs.
Underscoring the significant infrastructure needed to implement higher-order multi-MPS platforms, we sub-
stituted a commercial iPS-derived brain model for the 10-MPS experiment because its adult-derived nature and 
shorter maturation time facilitated workflow coordination to mature MPSs off platform in tandem. Also, the 
brain MPS configurations employed here lacked an explicit blood-brain-barrier (BBB), as BBB transport was 
not a focus of the drug studies analyzed here. However, the versatility of the platform design does not preclude 
accommodating an explicit BBB model from among many that have been described76, for applications where this 
feature is necessary. A similar analysis of the balance between performance, complexity, and cost as considera-
tions in the context of particular applications can be made for other MPSs.
The endometrium MPS illustrates additional trade-offs between complexity and function. The most common 
format for epithelial barrier MPSs, such as the lung and gut MPSs employed in this work, involve epithelial mon-
olayers plated on Transwell® inserts using well-defined protocols48,77–79. A more recent microfluidic epithelial cul-
ture barrier model developed by Huh and coworkers employs a porous PDMS membrane to support the epithelial 
layer, and is frequently combined with endothelial cells on the alternate side of the membrane63,80. The human 
endometrium is characterized by complex epithelial-stromal interactions, hence we developed and implemented 
a more complex model with epithelial cells on top of a 3D stromal layer, created by encapsulating the stromal cell 
line in a synthetic extracellular matrix (ECM) tailored to support the tissue integrity and function in long-term 
(4 week) culture81,82. The relative scarcity and variability of primary endometrial cells made the choice of cell lines 
more practical for these proof-of-principle studies, but we have demonstrated that this 3D epithelial barrier cul-
ture approach can be successfully applied to primary human endometrial cells81,82. Recent advances in expansion 
of primary human endometrial cells83,84 will make studies with primary endometrium – as well as other similarly 
finicky epithelial cells85 – more feasible in the future.
Another noteworthy finding from these multi-MPS interaction studies is that basic MPS functions can appar-
ently be maintained for weeks in interaction mode, with constant systemic circulation of the media among MPSs. 
In our model, we loaded each MPS on the platform in its specialized maintenance medium, operated the platform 
under systemic circulation conditions for two days, and then exchanged the medium within each MPS with fresh 
MPS-specific medium and the mixer with the common medium. (The fluidic channels, representing <1% of the 
total volume, were not exchanged). The standard systemic circulation rate we used of 0.5–1 total medium volumes 
per day is comparable to other multi-MPS platforms described in the literature30–36,53,56,57. Most MPSs showed at 
least comparable phenotypic metrics on the platform compared to off-platform (Figs 3, 4, 5 and S4–6). Notably, 
during platform interaction studies, the liver MPS converted a parent drug, DCF, to a known primary metabolite 
(4-OH-DCF) in a pharmacologically-relevant manner, indicating maintenance of CYP450 activity and suggesting 
that operational factors such as culture medium oxygenation are suitable. For the pancreas MPS and the brain 
MPS, which both showed improved metrics for a single representative phenotype viability (c-peptide and NAA 
production, respectively) on the platform compared to in isolation off-platform, a possible explanation is the 
presence of convection to enhance nutrient exchange on platform, compared to static conditions in isolation. 
However, we cannot rule out that factors produced or consumed by other MPSs on the platform influenced the 
observed function of the pancreas and brain MPSs. Encouragingly, a 6-fold increase in the systemic flow rate 
(i.e., a 6-fold increase in the exchange rate among MPSs compared to the standard rate) did not appear to have 
deleterious effects on MPS function; for example, albumin production was unaffected by this 6-fold escalation of 
exchange rate for several days (Fig. 6). These results add to the accruing data on how multi-MPS interactions can 
have both positive and negative effects on individual MPS function.
Finally, this work demonstrates how a QSP approach can be applied to plan and interpret pharmacological 
experiments in multi-MPS platforms, which becomes increasingly challenging as the number of MPSs increases. 
QSP approaches using PBPK models of our platforms were critical to identifying operational strategies for exper-
iments (drug dosing, sampling time points, inter- and intra-MPS media flowrates, etc.) to obtain informative 
results. By comparing our experimental results with the theoretical distribution values calculated from the PBPK 
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models in the studies of endogenous albumin distribution in the 4-MPS platform and exogenous oral drug dis-
tribution in the 7-MPS platform, we demonstrated that our multi-MPS platforms operate deterministically. This 
predictable and calculable platform operation enables the study of PK/PD (cue-response) relationships on such 
platforms in the future. Further, having models that capture the dynamics of molecular distribution throughout 
the platform means we can simplify experimental operation by collecting samples from the mixer only, and pre-
dict drug concentrations in the other compartments.
The experiments described here are proof-of-principle in nature, intended to demonstrate the capabilities of 
the platform technology and QSP approaches. While the technology is robust up to 10-way interactions, such 
substantial resources are required to operate in a 10-way mode (experimental design, MPS preparation, analysis 
of samples, etc.) that it is unlikely the technology will be widely deployed for such higher-order interactions in 
the near future. However, we anticipate that the platform technology is highly amenable to illuminating specific 
biological or pharmacological questions involving lower-order (2–4) interactions. We have recently deployed a 
2-way version of this platform to show cross-regulation of the liver MPS metabolic function in gut-liver interac-
tions during baseline and inflamed conditions30,36. These studies provide a foundation for ongoing work exam-
ining 4-way interactions between gut, pancreas, liver, and brain in various chronic diseases such as Parkinson’s86, 
where QSP approaches aid conceptualization of the platform configuration and scaling of MPSs. An outstanding 
question in both single and multi-MPS formats is how to replace the essential functions of missing MPSs (e.g. 
endocrine, etc.) for any given physiology or disease model, and technologies are emerging to address this need87.
In summary, we have demonstrated a generalizable approach to linking MPSs within a fluidic platform to cre-
ate a physiome-on-a-chip approach capable of generating complex molecular distribution profiles for advanced 
drug discovery applications. This adaptable, reusable system has unique and complementary advantages to exist-
ing microfluidic and PDMS-based approaches, especially for applications involving high logD substances (drugs 
and hormones), those requiring precise and flexible control over inter-MPS flow partitioning and drug distribu-
tion, and those requiring long-term (weeks) culture with reliable fluidic and sampling operation. We anticipate 
this platform can be applied to a wide range of problems in disease modeling and pre-clinical drug development, 
especially for tractable lower-order (2–4) interactions.
Methods
Platform Fabrication and Assembly. Device layers were designed in CAD and commercially machined. 
Pneumatic plates were machined in acrylic and solvent bonded to form two-layer manifolds, while fluidic plates 
were machined from monolithic polysulfone stock material. Pneumatic plates were post-processed with vapor 
polishing and fluidic plates were cryo-deburred to remove sharp burrs. The PU membrane was supplied by 
American Polyfilm Inc. and mounted onto grip rings (Ultron Systems UGR-12) to provide uniform tension. 
Mounted membranes were laser cut to remove material around screw holes, then sterilized using ethylene oxide 
gas.
Sterilized layers were assembled in a laminar flow hood, and the cell culture area of the device was cov-
ered with a standard multi-well plate lid. Screws, washers, and pneumatic tubing could then be inserted under 
non-sterile conditions. Prior to culture, platforms were primed overnight by filling the wells with 1% bovine 
serum albumin in PBS and running all pumps to passivate fluid-contacting surfaces. After priming, the fluid was 
aspirated and cell culture media was added to each well at the appropriate volumes (see Table S1). Sampling and 
media changes were performed every 48 hours by manually collecting and replacing the media. A GUI software 
interface was used to set flow rates and calibration adjustments, while also monitoring pressure and vacuum 
during the experiment.
MPS Preparation. Liver MPS. The liver MPS was prepared as previously described20,43. LiverChips® 
were assembled 4 days prior to experiment start and primed overnight with 1% BSA and Pen/Strep in PBS. 
Cryopreserved human primary hepatocytes and Kupffer cells (Life Technologies, HMCPMS and HUKCCS) 
were recovered according to supplier’s instructions. Polystyrene scaffolds (CN Bio Innovations) were coated 
with rat tail collagen I (BD 354236). Cell suspensions (10:1 HMCPMS: HUKCCS) were seeded (6.6 × 105 
cells per scaffold) into scaffolds housed in the platform or LiverChip® in cold hepatocyte seeding medium 
(Advanced DMEM + Cocktail A + FBS). After 24 hours, the media was changed to pre-culture media (Advanced 
DMEM + Cocktail B). On the third day, the medium was changed to Williams E medium + Cocktail B + 100 nM 
hydrocortisone and the experiment commenced.
Gut MPS. Gut MPS was prepared as previously described30. Briefly, Caco-2 (4-MPS system) or C2BBe1 (7- and 
10-MPS system) along with HT29-MTX-E21 cells (Sigma) were seeded onto rat tail collagen I- (Corning 354236) 
coated Transwell® inserts (Corning 3460) in a 9:1 ratio (1 × 105 cells/cm²) in 500 µL seeding medium. The top and 
bottom compartments of the Transwell® plate were fed with 500 µL and 1.5 mL of seeding medium respectively 
every 2–3 days. After 7 days, cells were switched to serum-free culture medium. The immune component of the 
gut MPS was comprised of dendritic cells differentiated from frozen stocks of Leukopak aliquots (STEMCELL 
Technologies 70500). Cells were thawed then isolated using the EasySep Human Monocyte Enrichment Kit 
(STEMCELL Technologies 19058) and differentiated in dendritic differentiation medium. After 7 days (day 20 of 
gut insert maturation), immune cells were harvested using Accutase (Gibco™ A11105-01) and seeded on to the 
basal side of the inverted gut Transwell® in gut basal medium. After 2 hours, cells were returned to culture plate 
and fed with gut basal medium and gut apical medium in the basal and apical compartments, respectively.
Lung MPS. Cryopreserved primary normal human bronchial epithelial (NHBE) cells (Lonza) were seeded 
at a density of 1.5 × 105 cells/cm2 on human placental collagen IV (Sigma-Aldrich) coated Transwell® inserts 
(Corning 3470). Cells were cultured in lung medium77 until confluence (2–3 days), and then maintained at the 
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air-liquid interface with basal media changes every 2 days for three weeks to induce differentiation into ciliated 
and secretory cell populations.
Endometrium MPS. The endometrium MPS, a co-culture of Ishikawa human endometrial epithelial adenocar-
cinoma cells (Sigma-Aldrich) and hTERT-immortalized human endometrial stromal cells (tHESCs) (ATCC), 
was prepared as previously described81. Briefly, polyethylene glycol (PEG) hydrogel matrices comprising 5 
wt/wt% PEG vinyl sulfone (PEGVS) (JenKem Technology, Beijing) functionalized with 2 mM total adhesion/
matrix-binding peptides (Boston Open Labs, Cambridge, MA), 4.2 × 106 tHESCs/mL, and 1.9 mM crosslinking 
peptide MMP-CL in 1x PBS, 1 M HEPES buffer (pH 7.8)) were fabricated in Transwell® inserts (Corning 3470). 
24 h after initiation of stromal cultures, Ishikawa cells were harvested via trypsinization, resuspended in DMEM/
F12/FBS and seeded at a density of 75,000 cells/Transwell® (225k cells/cm2) on top of gel-encapsulated stromal 
cells. Apical medium was changed 24 h after seeding to remove non-adherent epithelial cells, and constructs were 
cultured for an additional two days prior to the start of the experiment.
Brain MPS for 7-way. Polyethylene glycol (PEG) hydrogels were prepared according to a previously pub-
lished protocol22. Briefly, PEG hydrogels were prepared fresh, using 40 mg/mL 8-arm PEG-norbornene (Jenkem 
A10037-10) in 2x PBS containing KCGGPQGIWGQGCK peptide (ThermoFisher) at 60% cross-linking density 
(~19.2 mM), 2 mM CRGDS C-amidated peptide (ThermoFisher), and 0.05 wt% Irgacure I2959 (Sigma-Aldrich 
410896) initiator. Gels were polymerized in Transwell® inserts (Corning 3470) with 40 µL total volume and 4.8 J/
cm2 of 365 nm UV light (10 minutes, 8 mW/cm2).
Neural progenitor cells (NPCs) derived from the human H1 ES line were obtained as a gift from James 
Thomson, Morgridge Institute, Madison, WI. The NPCs were cultured in DMEM/F12 (Gibco 11330) supple-
mented with 220 µM L-ascorbic acid (Sigma-Aldrich A8960), 80 nM sodium selenite (Sigma-Aldrich S5261), 
6.5 mM sodium bicarbonate (Sigma-Aldrich S5761), 5 ng/mL human FGF-2 (Fisher Scientific 507515502), 
and N-2 and B27 supplements at 1X final concentration (Life Technologies 17502-048 and 17504-044). NPCs 
were maintained below 90% confluence on matrigel-coated polystyrene (Corning 354230) and harvested for 
MPS seeding with Accutase (ITC AT104) between passages 4–6. PEG hydrogels were swelled in DMEM/F12 for 
12–24 hours and then seeded with NPCs at a density of 50,000 cells/Transwell® in fresh NPC media. Neural con-
structs were cultured for 12–14 days to allow for expansion and differentiation of neuronal and glial subpopula-
tions, as confirmed by increased immunostaining for neural marker β3-tubulin and astrocyte marker GFAP. NPC 
media was changed every 48 hours, using 200 µL in the apical compartment, and 1 mL in the basal compartment.
Brain MPS for 10-way. CNS cells were obtained from Axiogenesis (CNS.4U, Cat #Ax-C-HZ02-2M) as a cryo-
preserved mixture of iPS-derived astrocytes and neurons (glutamatergic, GABAergic, and dopaminergic). Three 
days prior to interaction, Transwells® (24-well, 0.4 µm pore size) were matrigel coated (0.1 mg/ml in PBS) for one 
hour at 37 °C, then seeded with 200,000 freshly thawed cells. Cells were seeded and cultured in Neuro.4U media 
(Cat #Ax-M-NBM250) with DA supplement (Cat #Ax-M-DCS-DA) according to the manufacturer’s recommen-
dations. Constructs were transferred to platforms 2–4 days post-seeding. On-platform, apical media remained 
Neuro.4U + DA, while basal media was replaced with Common Media.
Heart MPS. Human iCell Cardiomyocytes 2 (Cellular Dynamics International, Inc CMC-100-012-000.5) were 
seeded at a density of 0.3 × 106 cells/cm2 onto human fibronectin coated Transwell® inserts (Corning 3470). 
Cardiomyocytes were cultured in plating media (CDI CMC-100-010) for 48hrs to recover and changed to main-
tenance media (CDI CMM-100-120) for an additional 48hrs prior to the start of the experiment.
Pancreas MPS for 7-way. Rat pancreatic islets were obtained from the Joslin Diabetes Center (Boston, 
MA), isolated according to standard isolation protocol88. Islets were delivered on ice, filtered upon arrival to 
achieve a size range of 70–140 µm diameter, and maintained in a non-tissue culture treated petri-dish with 
20 mL of RPMI media (Thermo Fisher, 72400047) supplemented with 0.125% BSA (Sigma, A9576) and 1% 
Penicillin-Streptomycin.
Three days before platform experiments began, 75 islets were handpicked under a stereo microscope and 
seeded into a polystyrene scaffold (CN Bio Innovations). The scaffold was sandwiched between two porous mem-
branes and held in place with retaining rings (CN Bio Innovations). The entire membrane-scaffold sandwich was 
contained within the custom-made removable insert (see platform section).
Pancreas MPS for 10-way. Rat pancreatic islets were obtained from the Joslin Diabetes Center (Boston, MA), iso-
lated according to standard isolation protocol88. Islets were delivered on ice, filtered upon arrival to achieve a size 
range of 70–140 µm diameter, and maintained in a non-tissue culture treated T75 flask with 10 mL of RPMI media 
(Thermo Fisher, 72400047) supplemented with 0.125% BSA (Sigma, A9576) and 1% Penicillin-Streptomycin.
Two days before platform experiments began, islets were spun down at 1000 rpm for 3 minutes, washed twice 
with Ca-free PBS (centrifuging after each step) and then resuspended in 1.5% alginate (Novamatrix, SLG20) in 
deionized water in a non-tissue culture treated petri-dish. Islets were then handpicked under a stereo-microscope 
for seeding. 25 islets (in 20 µL total volume) were seeded into each polyester Transwell® insert with 8 µm pore size 
and 33 mm2 surface area (Corning, 3464). After seeding, 20 µL of 20 mM BaCl2 solution (20 mM BaCl2-2H2O, 
2 mM KCl, 10 mM HEPES, 268 mM Mannitol, all from Sigma) was added to each Transwell®. The alginate was 
allowed to crosslink for 5 minutes at 37 °C then the Transwells® were washed three times with pre-warmed RPMI. 
Finally, 800 µL of RPMI was added to each well with 200 µL added inside the insert for a total of 1000 µL media 
volume per well.
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Muscle MPS. Primary Human Skeletal Muscle Myoblasts (Lonza CC-2580) were seeded at a density of 
0.24 × 106 cells/cm2 onto Human Fibronectin (Gibco 33016015) coated Transwells® (Corning 3470) in SkGM™-2 
Skeletal Muscle Cell Growth Medium-2 (Lonza CC-3245). Transwell® inserts contained 150μL apical volume and 
1 mL basal volume After 24 hours, myoblasts were changed to differentiation media (DMEM-F12 with 2% Horse 
serum) for an 4 days, changing media every 48 hours, and subsequently returned to SkGM™-2 Skeletal Muscle 
Cell Growth Medium-2 at the start of the experiment.
Skin MPS. The in vitro skin model was purchased from EpiSkin (Lyon, France) and consists of reconstructed 
human epidermis from normal human keratinocytes cultured on a collagen matrix at the air-liquid interface. The 
EpiSkin kit (EpiSkin Large model 1.07 cm2) was shipped at Day 13 of maturity in nutrient agar. Upon receipt of 
the EpiSkin kit, the inserts were transferred from their nutrient agar under aseptic conditions into a sterile culture 
multi-well plate containing 2 ml per well of pre-warmed differentiation medium (L’Oreal DIFF + ). Medium was 
replaced every 48 hours.
Kidney MPS. Human Renal Proximal Tubule epithelial cells (RPTEC) were plated in RPTEC growth media- 
DMEM:F12 supplemented with EGF (10ng/mL), Hydrocortisone (36ng/mL), Triiodothyrine (2 pg/mL), 
ITS (1:1000), Pen/Strep (100 U/mL) onto human placental Collagen IV (Sigma Aldrich cat.# C5533) coated 
Transwells® (Corning 34130) at a density of 0.075 × 106 cells/ cm2. Transwell® inserts contained 200μL apical vol-
ume and 1 mL basal volume. Full apical media volume and half basal media volume were replaced every two days.
Platform Operation and Sample Collection. Mature constructs were transferred to the platform and 
cultured for the duration of the experiment in multi-MPS interaction. Basal and apical media was changed every 
two days, with samples collected from each compartment and stored at −80 °C.
Table S1 outlines the compartmental volumes and flow rates used in all the experiments. The systemic flow 
rate (output from the mixer) was computationally determined to enable proper mixing of endogenously produced 
biomolecule and exogenously added drugs. The computational methodology was adapted from our previous 
work38 and is described in Supplementary Materials. The flow partitioning from the mixer to each MPSs was 
scaled based on physiological cardiac output to each tissue type in human.
MPS Metric Measurements. Liver MPS. Samples from each compartment were assayed for albumin 
using a human-specific ELISA (Bethyl Labs E80-129).
Gut MPS. Barrier integrity was quantified by TEER using the EVOM2 and the Endohm-12 (World Precision 
Instruments) at 37 °C.
Lung MPS. Lung cultures were incubated for 2 hours with 150 µL 1 × PBS in the apical compartment. After 
removal of wash buffer, barrier integrity was quantified by TEER using the EVOM2 and the Endohm-6 (World 
Precision Instruments) at 37 °C.
Endometrium MPS. Secreted IGFBP-1 protein was quantified by ELISA for IGFBP-1 (R&D systems DY871)81. 
Manufacturer methods were adapted for 384-well plate (ThermoFisher 464718) to minimize required sample 
volume.
Brain MPS. N-acetylaspartate in samples from the apical side of the brain MPS was quantified by LC-MS/MS by 
Alliance Pharma. The analytical methods are described in detail in the supplementary material.
Heart MPS. Cardiomyocyte beating was monitored every four days using with a Leica DMI 6000 Microscope 
(37 °C, 5% CO2) and Oasis Surveyor software and recorded as videos using Open Broadcast software. Beat fre-
quency was extracted from the video files using Matlab.
Pancreas MPS. C-peptide was quantified by ELISA (80-CPTRT-E01, ALPCO).
Muscle MPS. Myostatin was quantified by ELISA (DGDF80, R&D).
Skin MPS. TEER measurements were performed according to a protocol adapted from a publication by 
the L’Oreal Research group89. TEER was measured using the EVOM2 and the Endohm-12 (World Precision 
Instruments) and D-PBS (Ca2+, Mg2+) as an electrolyte solution. The day of TEER measurement, 0.3 ml of 
D-PBS was added onto the apical side of the insert and left to equilibrate for 15 min at 37 °C, and 2.5 ml of D-PBS 
were added inside an EndOhm Chamber. Following TEER measurements, D-PBS was removed from the apical 
side to restore the air-liquid interface.
Kidney MPS. TEER was measured using the EVOM2 and Endohm-6 chamber (World Precision Instruments) 
at 37 °C.
Computational analysis of albumin and diclofenac kinetics. Computational investigations of the 
experimental output and graphical analyses were performed in Matlab R2016a (The MathWorks Inc., Natick, 
MA). The details of computational models are presented in the supplementary materials.
In brief, the experimentally observed albumin and DCF distribution kinetics data on-platform were analyzed 
with the aid of mechanistic in vitro PBPK models, the structure of which was guided by the MPS interconnection 
scheme and the physiological processes taking place on-platform. The developed mechanistic models utilized 
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fixed values for operational and certain biological parameters, and were fitted to the experimental data (across 
all platform compartments and time points simultaneously) to estimate specific model parameters that represent 
processes of interest in each experiment: rate of production of albumin by liver MPS in the 4-way albumin dis-
tribution experiment, and pharmacokinetic processes (e.g. intrinsic hepatic clearance of DCF and the fraction 
converted to 4-OH-DCF by the liver MPS) in the 7-way DCF kinetics experiment. The details of computational 
models and their application are presented in the supplementary materials.
The analytical methods using mass spectrometry are described in detail in the supplementary material. For 
drug quantification, we developed a 3-in-1 assay, which can quantify diclofenac, 4-OH diclofenac, and hydrocor-
tisone (results not shown) simultaneously.
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